-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Hopewell, New Jersey, USA, Cambridge, Massachusetts, and Beijing , China , November 23, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) is a global A biotech company focusing on the development and commercialization of innovative drugs worldwide
After the development plan is finalized, in addition to the purchase of land, BeiGene expects to invest hundreds of millions of dollars in the initial construction of the park
BeiGene Co-founder, Chairman and CEO John V.
Governor Phil Murphy said: "We are very pleased that BeiGene has chosen New Jersey as the next step in the global production of innovative anti-cancer drugs
Hopewell Mayor Julie Blake said: “As more companies like BeiGene settle in the West Princeton Innovation Park, Hopewell Town’s priority as a biotechnology base in the future will become more stable
BeiGene acquired Hopewell related assets from Lincoln Equities Group and continues to retain DPR Construction as its construction management company and IPS as its construction engineering company
About BeiGene
BeiGene is a science-based global biotechnology company focusing on the development of innovative and affordable medicines, aiming to improve treatment outcomes and access to medicines for patients around the world
Forward-looking statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including BeiGene’s plans and the anticipated establishment of a new production and R&D facility in New Jersey The center, to produce commercial drugs and drug candidates at the base, to further diversify BeiGene's global supply chain, the estimated timetable for the acquisition of the land and the construction of facilities, and the expected recruitment of talents for the new production and R&D center by BeiGene Investment, and BeiGene’s plans, commitments, ambitions, and goals mentioned under the subheading "About BeiGene"
